R. C. Seeger

发表

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

K. Matthay, R. Gerbing, J. Villablanca, 1999, The New England journal of medicine.

Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

K K Matthay, D O Stram, D. Stram, 1999 .

Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.

A. Look, M. Valentine, G. Brodeur, 1995, Cancer research.

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.

D. Stram, K. Matthay, R. Gerbing, 2001, Medical and pediatric oncology.

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

D. Stram, K. Matthay, R. Gerbing, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

S. Groshen, B. Franc, J. Maris, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification.

J. Strahler, R. Seeger, F. Lottspeich, 1991, The Journal of clinical investigation.

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

D. Stram, J. Maris, K. Matthay, 2001, Medical and pediatric oncology.

Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.

D. Stram, K. Matthay, R. Gerbing, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.

D. Stram, K. Matthay, E. Gerstner, 2000, Journal of pediatric hematology/oncology.

Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma.

D. Stram, K. Matthay, M. Selch, 1994, Progress in clinical and biological research.

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.

D. Stram, K. Matthay, R. Seeger, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.

S. Feig, J. Buckley, K. Matthay, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

K. Matthay, S. Burchill, R. Seeger, 2009, British Journal of Cancer.

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.

J. Maris, P. White, M. Hogarty, 2001, Cancer research.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

J. Maris, W. London, R. Seeger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

D. Stram, K. Matthay, H. Shimada, 2010, The New England journal of medicine.

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

D. Stram, J. Maris, K. Matthay, 2001, Medical and pediatric oncology.